Recently added
This page was added on 27 June 2024.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Monoclonal antibody for the prevention of serious lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (CHD).
Palivizumab 50 mg/0.5 mL single-use vial: clear, colourless Type 1 glass vial with stopper and flip-off seal containing 0.5 mL palivizumab solution for injection with a concentration of 50mg/mL
Palivizumab 100 mg/1 mL single-use vial: clear, colourless Type 1 glass vial with stopper and flip-off seal containing 1 mL palivizumab solution for injection with a concentration of 100mg/mL
Also contains:
- 25mM histidine
- 1.6 mM glycine
For Product Information and Consumer Medicine Information about Synagis (palivizumab) visit the Therapeutic Goods Administration website.
Additional information
For detailed advice on dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.